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Abstract
Introduction: Osteoporosis and cardiovascular diseases (CVD) are more common in the elderly population and have similar risk factors.
The goal was an evaluation of the correlation between 10-year risk of death from CVD and 10-year bone fracture risk (FRAX).
Material and methods: A total of 79 patients of the Regional Centre of Menopause and Osteoporosis of the Military Teaching Hospital in Lodz 
(Poland), aged 50–83 years, consulted for osteoporosis were divided into two groups: study group — with osteoporosis (O; T-score ≤ –2.5 SD) 
and control — without osteoporosis (T-sc > –2.5). Bone mineral density was evaluated by densitometric scanning of spine (L2-L4 T-score) 
and/or femoral neck (Neck T-score) and/or total hip (Total Hip T-score). Total cholesterol (TC), fasting glucose, arterial blood pressure, 
medical history, and family history were obtained. The risk of fatal-CVD was assessed by Euro Heart Score (EHS), and major osteoporotic 
(MOFR) and hip fracture risk (HFR) by the FRAX scale.
Results: 80% of the patients (32/40) with osteoporosis and 51% (20/39) of the patients without osteoporosis revealed a HeartScore ≥ 5%. 
There was correlation in the group of all patients between EHS and Neck T-score (p < 0.05; Spearman rank correlation coefficient (Rs) 
= –0.3806), L2-L4 T-score (p < 0.05; Rs = –0.2891), and Total Hip T-score (p < 0.005; Rs = –0.3561), and in the control group — between 
EHS and Neck T-score (p < 0.05; Rs = –0.3502). There was a 2.33% difference between the average EHS level to the disadvantage of 
patients with osteoporosis (p < 0.05). EHS positively correlated with MOFR (p < 0.001) and HFR (p < 0.001) in the whole study popula-
tion and with MOFR (p < 0.05) and HFR (p < 0.01) in the group of osteoporotic patients. There were differences between groups in TC 
(p < 0.001) and BMI (p < 0.001) levels.
Conclusions: The 10-year risk of fatal-CVD correlated with osteoporosis and with the 10-year osteoporotic fracture risk. This conclusion 
may help identify patients who require extended cardiotherapy protocols. (Endokrynol Pol 2017; 68 (4): 390–397)
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Streszczenie
Wstęp: Osteoporoza i choroby układu sercowo-naczyniowego (CVD) występują częściej w populacji osób w starszym wieku i posiadają 
podobne czynniki ryzyka.
Cel: Ocena korelacji pomiędzy 10-letnim ryzykiem zgonu z powodu CVD oraz 10-letnim ryzykiem złamań kości (FRAX) u pacjentów 
z osteoporozą.
Materiał i metody: 79 pacjentów z Regionalnego Ośrodka Menopauzy i Osteoporozy (Uniwersytecki Szpital im. WAM w Łodzi, Polska), 
w wieku 50–83 lat, konsultowanych pod kątem osteoporozy, podzielono na 2 grupy ze względu na badanie densytometryczne (T-score): 
grupa badana — z osteoporozą (O; T-score ≤ –2,5 SD) i kontrolna — bez osteoporozy (T-score > –2,5). Uzyskano następujące informacje: 
wywiad medyczny, BMI, elektrokardiogram; za pomocą kwestionariusza: czynniki ryzyka osteoporozy, wywiad w kierunku chorób ser-
cowo-naczyniowych m.in. udaru, zawału serca (MI), choroby niedokrwiennej serca (CAD), nadciśnienia tętniczego (HA), cukrzycy (DM), 
wywiad rodzinny w kierunku tych schorzeń. Dokonano także densytometrycznej oceny gęstości mineralnej kości (BMD): kręgosłupa 
(L2-L4 T-score) i/lub szyjki kości udowej (Neck T-score) i/lub całego biodra (Total Hip T-score). Ponadto, oznaczono poziom całkowitego 
cholesterolu (TC) i glukozy na czczo (GLU) w surowicy oraz zmierzono ciśnienie tętnicze krwi (BP). Ryzyko wystąpienia incydentu 
sercowo-naczyniowego zakończonego zgonem (Fatal CVD) oceniono przy pomocy skali Euro Heart Score (EHS) dla populacji polskiej. 
Ryzyko złamań oceniono przy pomocy skali FRAX dla całkowitego ryzyka złamań (Major Osteoporotic Fracture Risk — MOFR), oraz ryzyka 
złamań kości udowej (Hip Fractures Risk — HFR).
Wyniki: 80% pacjentów (32/40) z osteoporozą i połowa pacjentów bez osteoporozy (20/39) uzyskała HeartScore ≥ 5%. Wykazano istotną staty-
stycznie negatywną korelację w grupie wszystkich pacjentów pomiędzy EHS and Neck T-score (p < 0,05; Spearman rank correlation coefficient (Rs) 
= –0,3806), L2-L4 T-score (p < 0,05; Rs = –0,2891), Total Hip T-score (p < 0,005; Rs = –0,3561), jak również w grupie kontrolnej tylko pomiędzy 
EHS and Neck T-score (p < 0,05; Rs = –0,3502). Stwierdzono również znamienne różnice pomiędzy średnim poziomem EHS w obu grupach 
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The facts and statistics about osteoporosis in the world 
indicate that approximately 200 million people suf-
fer from this medical condition, with a 15–30% male 
population above the age of 50 years and 30–40% post-
menopausal women. Osteoporosis is a chronic disease, 
concomitant with other medical conditions, including 
coronary arterial disease (CAD), arterial hypertension 
(HA), and other cardiovascular disorders [1–8]. 
The incidence of both osteoporosis and CVD grows 
with age [2, 6]. Attention should be drawn to the ob-
served coexistence of the same risk factors for osteopo-
rosis and cardiovascular diseases, except the age, which 
include sedentary lifestyle, impaired lipid metabolism, 
tobacco smoking, and excessive alcohol consumption [5], 
similarly to the presence of the same proinflammatory 
markers (including CRP, IL6, TNF-α, and TNF-β) [2]. All 
this suggests a common pathophysiological mechanism, 
which may underlie both medical conditions. 
It is an important fact that both osteoporosis and 
cardiovascular disorders are associated with a signifi-
cant risk of disability and mortality, while only a few 
studies have attempted to analyse both diseases as 
related conditions [9–12]. 
Thus, the primary question was raised whether 
there was any relationship between the 10-year risk of 
death from cardiovascular diseases and the 10-year risk 
of osteoporotic fracture.
Material and methods
The study comprised 79 patients of the Regional Centre 
of Menopause and Osteoporosis of the Military Teach-
ing Hospital in Lodz (Poland), treated during the years 
2009–2013, who signed an informed consent form. 
The enrolled patients included postmenopausal 
women at the age of 50–83 years (the mean age: 67 years). 
The patients were randomly assigned to the study 
and divided into two groups: a group with osteoporosis 
(40 patients) and a control group without osteoporosis 
(39 patients, including 29 with osteopenia and 10 healthy 
subjects). The division was made according to WHO 
criteria after densitometric scanning of the spine (T-score 
of lumbar spine [L2-L4]) and/or femoral neck (T-score of 
Neck) and/or total hip (T-score of Total Hip), performed 
by dual-energy X-ray absorptiometry (DXA), where the 
T-score BMD ≤ –2.5 SD revealed osteoporosis. Patients who 
had T-score BMD from –2.5 to –1.0 SD were diagnosed to 
have osteopenia. The densitometer GE Lunar Prodigy was 
used. The minimum acceptable precision for technologists 
in our facility does not exceed the following values: 1.9% 
(LSC = 5.3%) for Lumbar Spine, 1.8% (LSC = 5.0%) for 
Total Hip, and 2% (LSC = 5.5%) for Femoral Neck.
Both groups were at similar ages, without any sig-
nificant differences. The mean age of the patients with 
osteoporosis was 68 ± 6.8 years (mean ± SD) (56–80 
years old; five patients below 60 years old) and of those 
without osteoporosis was 66 ± 7.8 (mean ± SD) years 
(50–83 years; eight patients below 60 years old). 
The data were obtained from medical history. Two 
questionnaires and additional tests were carried out 
by means of ESC EuroHeart Score (EHS) [13, 14] and 
WHO FRAX score [15] requirements.
The acceptance of the Local Bioethical Committee 
was obtained before setting the study. Patients signed 
an informed consent form before the study.
Questionnaires
Two questionnaires were employed: (1) cardiological, 
enquiring about tobacco smoking, diabetes mellitus (DM), 
hypertension (HA), ischaemic heart disease (IHD), and 
myocardial infarction (MI) and/or cerebral stroke, in the 
examined patients plus the incidence of the same diseases 
and sudden cardiac death (SCD) in the closest family 
members (father, mother, siblings); and (2) osteoporotic, 
where, among others, risk factors for osteoporosis were 
considered, comprising: occupational activity, manual 
work, tobacco smoking, coffee consumption, calcium 
supplementation, fractures in patient’s medical history, 
fractures in family medical history, and chronic glucocor-
ticosteroid (GCS) therapy.
Additional procedures
Patient’s height and weight were measured without 
shoes and in light clothes. A stadiometer SECA 206 was 
used to measure height. The arterial blood pressure — 
systolic and diastolic — was measured (on an arm after 
a five-minute rest) with a sphygmomanometer. BMI 
was calculated from body height and weight inputs. 
(p < 0,05) — 2,33%, na niekorzyść pacjentów z densytometrycznymi cechami osteoporozy. EHS pozytywnie korelowało z MOFR (p < 
0,001) i HFR (p < 0,001) u wszystkich pacjentów. Ponadto zaobserwowano istotne korelacje pomiędzy EHS i MOFR (p < 0,05) i HFR (p 
< 0,01) w grupie pacjentów z osteoporozą. Obie grupy różniły się istotnie pod względem średnich poziomów TC (p < 0,001) i wartości 
BMI (p < 0,001).
Wnioski: Dziesięcioletnie ryzyko zgonu z powodów sercowo-naczyniowych korelowało z występowaniem osteoporozy oraz 10-letnim 
ryzykiem złamań osteoporotycznych. Wyciągnięte wnioski mogą pomóc w identyfikacji grupy pacjentów wymagających poszerzenia 
leczenia kardiologicznego. (Endokrynol Pol 2017; 68 (4): 390–397)
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ECG was taken by AsCARD Mr Silver ver. 2.24 (with 
particular attention paid to features of experienced 
myocardial infarction and features of ischaemia). Fast-
ing glucose (measured by ContourTS glucometer) and 
total cholesterol levels (measured by MultiCareIn) were 
assayed in capillary blood by semi-quantitative method, 
prior to drug intake (off medications on the day when 
measurements were made; there was no long-time 
pause in drug intake).
EuroHeart Score
The 10-year risk of death from cardiovascular diseases 
was assessed by means of the EuroHeart Score (EHS). 
The so-called high-risk card was used, which is ad-
equate for countries of Central-Eastern Europe, includ-
ing Poland. The scale took into account the following 
five parameters: sex, age, tobacco smoking, systolic 
blood pressure, and total cholesterol level. Scores ≥ 5% 
were regarded as high risk. EuroHeart Score is a broadly 
used scale recommended by the European Society of 
Cardiology [13, 14, 16].
FRAX Score
Using the FRAX Score tool, the 10-year fracture risk was 
evaluated in two domains: major osteoporotic fracture 
risk (MOFR) and hip fracture risk (HFR), using the 
Poland-adjusted FRAX version. The scale considered 
12 factors: age, sex, weight, height, fracture history, hip 
fractures in family history, actual tobacco smoking, GCS 
therapy, rheumatoid arthritis, secondary osteoporosis, 
alcohol consumption, and Femoral Neck DXA results. 
According to the Polish guidelines [15], values ≥ 10% 
of MOFR and ≥ 3% of HFR were interpreted as high. 
The FRAX Score scale is increasingly prevalent and its 
application is recommended in Poland [15].
Statistics
The mean results were expressed as mean ± SD. The 
level of statistical significance was set at p < 0.05 (5%). 
Pearson’s correlation coefficient (Rp) and Spearman’s 
rank correlation coefficient (Rs) were used, where R = 0–1 
(strong — R = 0.5–1, weak — R = 0–0.5) were assumed to 
be positive correlations. To check the correlation with 0/1 
(absent/present) data the Mann-Whitney test was used. 
Results
Bone Mineral Density and T-score
The mean T-score in the control group was –1.3 ± 0.8 
(the lowest score at –2.2 SD), while in the study group, 
the average and the lowest T-score values were –2.9 ± 
0.8 and –4.9 SD, respectively. The mean T-score in all 
examined sites (Neck, L2-L4, Total Hip) is presented 
in Table I.
Total cholesterol and BMI
The mean TC levels significantly differed between the 
groups (p < 0.001). Higher TC levels were observed in 
patients with osteoporosis (see Table I). The mean TC 
level value in the control group was 194 ± 28 mg/dL, 
which was interpreted as slightly elevated (following 
the recommended by European Society of Cardiology 
(ESC) norm < 190 mg/dL) [14]. Twenty-one patients ob-
tained the TC levels ≥ 195 mg/dL, 4 ≥ 250 mg/dL, while 
the mean TC level in the study group was definitely 
higher, amounting to 233 ± 52 mg/dL (35 patients were 
TC ≥ 195 mg/dL, 13 ≥ 250 mg/dL: two over 300 mg/dL, 
and one over 400 mg/dL). The highest TC values were 
also higher in the study group than in the control 
group (400 mg/dL and 252 mg/dL, respectively). Con-
versely, the mean BMI in the control group was 27.6 ± 
3.5 (which corresponds to overweight) and 24.4 ± 3.4 
in the study group (not exceeding the normal limits). 
The BMI levels significantly differed between groups 
(p < 0.001).
Arterial pressure
No significant differences were observed between the 
mean arterial pressure values (systolic and diastolic) 
(see Table I). However, higher maximal and minimal 
systolic and higher maximal and minimal diastolic 
pressure values were noted in the study group. It was 
most distinctive in the case of the maximal diastolic 
pressure, which was 106 mmHg in the control group 
and 138 mmHg in the study group (a difference of 32 
mmHg) and, what is more important, in the course of 
CVD and for the maximal systolic pressure, where it 
was 202 mmHg in the control group and 223 mmHg in 
the study group (a difference of 19 mmHg). 
Fasting glucose level
An analysis of the mean fasting glucose level and DM 
occurrence did not indicate any differences between 
the two groups. The mean fasting glucose level was 
94 mg/dL — equal in both groups (see Table I). In the 
control group there was statistically significant negative 
correlation between fasting glucose level and L2-L4 
T-score (p < 0.05; Rs = –0.5135).
EuroHeart Score and FRAX Score
The ESC score was significantly higher (p < 0.05) in the 
osteoporotic group (7.95 ± 5.7) than in the control group 
(5.61 ± 4.3). The maximal EHS value in the group of 
patients with osteoporosis was 10% higher than in the 
group without osteoporosis (in the osteoporosis group 
the highest EHS was 30%, while in the control group 
it was 20%). None of the patients with osteoporosis 
obtained EHS < 1% (i.e. low mortality risk). It is worth 
emphasising that 80% of the patients from the study 
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group demonstrated a high 10-year risk of death from 
cardiovascular diseases, while in the control group it 
was approximately 50% of the patients.
As we expected, the higher FRAX scores were noted 
in the group of patients with osteoporosis. The sig-
nificantly higher values were present in both domains: 
MOFR (p < 0.001), as well as HFR (p < 0.001) (see 
Table I). According to cut-off MOFR and HFR values, 
respectively, 60% and 85% of patients with osteopo-
rosis revealed high fracture risk. The corresponding 
values in the control group were merely 8% and 10%, 
respectively. The differences between the mean FRAX 
scores were 9.5% and 8% in the MO and H domains, 
respectively.
Table I. Parameters: measured and calculated (mean ± SD; in the upper part of the table) and obtained from Osteoporosis 
questionnaire (in %; in the lower part of the table). The p < 0.05 (5%) was considered as statistically significant (marked with *)
Tabela I. Parametry: zmierzone i policzone (średnia ± SD; w górnej części tabeli) oraz uzyskane z wywiadu zebranego za 
pomocą kwestionariusza (%; w dolnej częsci tabeli). p < 0,05 (5%) — istotne statystycznie (zaznaczone przy użyciu *)
Type Parameter Control group Osteoporosis group p-value
Measured/calculated Mean ± SD
EHS [%] 5.61 ± 4.3 7.95 ± 5.7 < 0.05*
MOFR [%] 5.53 ± 2.9 15.36 ± 11.0 < 0.001*
HFR [%] 1.47 ± 1.8 8.61 ± 9.7 < 0.001*
T-sc Neck –1.2 ± 0.8 –2.4 ± 0.7 < 0.001*
T-sc Total –0.6 ± 0.9 –1.8 ± 0.9 < 0.001*
T-sc L2-L4 –1.1 ± 1 –2.6 ± 0.9 < 0.001*
Age [years] 66 ± 7.8 68 ± 6.8 NS
BP systolic [mmHg] 135 ± 24.1 138 ± 20.9 NS
BP diastolic [mmHg] 79 ± 11.2 80 ± 13.4 NS
Fasting glucose [mg/dl] 94 ± 12.7 94 ± 24.8 NS
TC [mg/dl] 194 ± 28.4 233 ± 52.0 < 0.001*
BMI 27.6 ± 3.5 24.4 ± 3.4 < 0.001*
Obtained from 
questionnaires (towards 
osteoporosis and towards 
baseline heart events)
%
Tobacco smoking 18 25 NS
GCS 5 13 NS
Retired 87 78 NS
Lack of physical effort 77 68 NS
Coffee consumption 3 3 NS
Diet low in calcium 21 18 NS
Bone fractures 31 43 NS
Bone fractures in family 18 13 NS
Stroke 5 5 NS
MI 13 3 NS
CAD 31 28 NS
HA 41 46 NS




Stroke in family 33 33 NS
MI in family 23 28 NS
CAD in family 51 50 NS
HA in family 51 43 NS
DM in family 33 23 NS
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Correlation between EHS and T-score and FRAX
There were statistically significant negative correlations 
in the whole study population between EHS and Neck 
T-score (p < 0.005; Rs = –0.3806), and L2-L4 T-score 
(p < 0.05; Rs = –0.2891) and Total Hip T-score (p < 0.005; 
Rs = –0.3561) (see Fig. 1). We found also statistically 
significant negative correlation in the control group, 
but only between EHS and Neck T-score (p < 0.05; 
Rs = –0.3502) (see Fig. 2). In the study group, we did 
not observe any significant correlations between EHS 
and T-score values.
Statistical analysis revealed also a positive correla-
tion between EHS and FRAX score in the whole study 
population in the MOFR domain (p < 0.001; Rp = 0.3) 
and in the HFR domain (p < 0.001; Rp = 0.34). 
We have also noticed a positive correlation between 
EHS and FRAX scores in the MOFR domain (p < 0.05; 
Rp = 0.27) and the HFR domain (p < 0.01, Rp = 0.34) 
in the study group. It should be noted that in the whole 
study population and in the group of patients with 
osteoporosis there was a stronger correlation between 
the 10-year cardiovascular mortality risk and the 10-year 
risk of hip fracture than between the above parameter 
and the 10-year risk of major fractures, the former being 
in a localisation typical for osteoporosis. We found no 
statistically significant correlations between EHS and 
fracture risk values in the control group.
Cardiological history
We did not find any significant differences between the 
groups in terms of occurrence of DM, HA, and episodes 
of stroke or MI in the past. The data on myocardial 
infarction episodes were verified by ECG recordings. 
What is interesting, 100% of patients without osteopo-
rosis after MI reported MI in the obtained history, while 
only one third of the patients with osteoporosis were 
aware of experienced MI.
There was statistically significant positive correla-
tion between the presence of electrocardiographic 
signs of MI in the past and EHS in the control group 
(p < 0.05; Rs = 0.3678) and in the whole study popula-
tion (p < 0.05; 0.2806). Due to the nature of the variables 
a Mann-Whitney test was performed, which showed 
that in both cases there was significant difference in the 
levels of EHS (Score) depending on the changes in ECG.
It should be emphasised that the statistical analy-
sis revealed a higher correlation between the risk of 
mortality for CVD and the number of cardiovascular 
diagnosed diseases in the patients with osteoporosis 
than in those without osteoporosis. For example, the 
same risk of death (e.g., 5%) was found in case of the 
almost twice lower number of cardiological disorders 
in the patients with osteoporosis –0.4 (p < 0.05; Rp = 
0.29) than in those without osteoporosis –0.9 (p < 0.001; 
Rp = 0.45). There was also statistically significant positive 
correlation between EHS and cardiological history in the 
control group (p < 0.005; Rs = 0.4983) (see Fig. 3) and 
in the whole study population (p < 0.005; Rs = 0.3599).
Figure 1. Correlation between Euro Heart Score and Neck 
T-score (p < 0.005; Rs = –0.3806), Total Hip T-score (p < 0.005; 
Rs = –0.3561) and L2-L4 T-score (p < 0.05; Rs = –0,2891) in 
the group of all patients
Rycina 1. Korelacja między Euro Heart Score i Neck T-score 
(p < 0,005; Rs = –0,3806), Total Hip T-score (p < 0,005; Rs 
= –0,3561) i L2-L4 T-score (p < 0,05; Rs = –0,2891) w grupie 
wszystkich pacjentów
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In the subpopulation of patients with osteoporosis we 
have observed a clear statistical trend to positive cor-
relation (Rp = 0.1979; p = 0.096), between „better” (less 
positive) family history towards cardiological episodes 
(concerning almost all the discussed disease entities) 
and 10-year risk of fatal CVD. 
Medical history towards osteoporosis
After gathering medical history, we did not find any 
significant differences between the groups, accord-
ing to the tobacco smoking, exposition to GCS, coffee 
consumption, calcium intake with diet, osteoporotic 
fractures, and bone fractures in family members. How-
ever, in the osteoporotic group, there was a higher 
percentage of patients supplemented with calcium 
compounds and exercising with physical effort on 
a daily basis. We were surprised to notice statistically 
significant positive correlation between L2-L4 T-score 
and medical history towards osteoporosis (number of 
osteoporotic risk factors according to a questionnaire) 
(p < 0.05; Rs = 0.2636) in the whole study population.
Discussion
As has been demonstrated, low bone-mineral density 
(BMD) levels may be associated with cardiovascular 
diseases [2–4, 6, 7, 17, 18]. The results of our study con-
firmed higher 10-year risk of fatal CVD in patients with 
osteoporosis. Moreover, we found that as many as 80% 
of the patients with osteoporosis qualified to the high 
(> 5%) 10-year CVD mortality risk group, while in the 
group of non-osteoporotic patients only 50% of patients 
had high CVD mortality risk. A similar association 
between low BMD at the menopause and mortality 
from cardiovascular diseases can be found in literature 
[12]. After the MORE study some authors went a step 
further, describing a strong linear association between 
the severity grade of osteoporosis and future risk of 
cardiovascular events [11].
There were similar numbers of patients with HA as 
well as with DM in both groups (with no statistical sig-
nificance). The literature reports broadly inform about 
higher incidence rates of osteoporosis in patients affect-
ed by arterial hypertension and type 1 diabetes mellitus 
[2, 3, 19] and about increased risk of bone fractures in 
patients with DM t. 2 [20] (RAC-OST-POL study showed 
also that diabetes t. 1 increased the risk of fall [21]) — in 
our study, probably, it would be easier to illustrate the 
difference in the case of a higher number of patients.
The literature reports a higher prevalence of ischae-
mic heart disease in patients with osteoporosis and 
osteopenia than in those without these two medical 
conditions [6]. The results obtained in our study are 
rather divergent regarding that particular aspect. Ac-
cording to medical history, IHD occurred with similar 
frequency in both groups of patients (as well as MI). 
What is interesting, 100% patients without osteoporosis 
after MI reported MI in the obtained history, while only 
one third of the patients with osteoporosis were aware of 
experienced MI (it could be suspected that those patients, 
being unaware of the cardiac medical condition, did not 
undertake any secondary prevention, which was asso-
ciated with a much higher risk of fatal CVD outcome). 
CT-angiography of the coronary arteries, carried out in 
that group of patients, would be another important step 
towards evaluation of the incidence and progression of 
ischaemic disease. 
Figure 2.  Correlation between Euro Heart Score and Neck T-score 
in control group (p < 0.05; Rs = –0.3502)
Rycina 2. Korelacja między Euro Heart Score i Neck T-score w 
grupie kontrolnej (p < 0,05; Rs = –0,3502)
Figure 3. Correlation between Euro Heart Score and cardiological 
history (number of cardiological entities in history) in control 
group (p < 0.005; Rs = 0.4983)
Rycina 3. Korelacja między Euro Heart Score i wywiadem 
kardiologicznym (liczba jednostek kardiologicznych w wywiadzie) 
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Moreover, the statistically significant correlations 
were described between EHS and Neck, Total Hip, 
and Lumbar Spine (L2-L4) T-score in the whole study 
population and between EHS and Neck T-score in the 
control group. Neck T-score seems to be the most valu-
able predictor of fatal-CVD. What is more, the 10-year 
risk of fatal CVD risk, observed in that group of patients, 
significantly correlated with the 10-year risk of major 
fractures and hip fractures. We also found similar results 
in the literature: women with the highest risk of CVD 
have a higher risk of major osteoporotic fractures [10], 
which may be associated with the pathophysiologi-
cal disorders common in both processes. A common 
pathogenesis of the two medical conditions may, for 
example, indicate mutual correlations of medicinal 
agents, exerted on particular disease entities. For exam-
ple, anti-atherosclerotic statins influence BMD levels, 
while anti-resorptive bisphosphonates reduce the for-
mation of arterial calcifications [18]. On the other hand, 
cardiovascular episodes are more frequently observed 
in patients on large-dose (1000–2000 mg) calcium sup-
plementation — lower doses seem to be safe (800 mg 
should be adequate as long as optimal vitamin D levels 
are ascertained) [8].
In our study, higher total cholesterol levels (me-
dium, maximal and minimal) were observed in the 
patients with osteoporosis, which may have supported 
atherosclerotic changes and atherosclerosis-related 
complications. Metabolic disorders find solid confirma-
tion in literature reports, which bring up examples of 
cases with the elderly, in whom metabolic disturbances 
overtly correlated with atheromatosis and osteoporosis 
progression. That particular concomitance of medical 
conditions can be explained by the fact that dyslipi-
daemia (especially the rise of LDL, with a simultane-
ous fall of HDL) plays a major role in the process of 
atheromatous plaque formation (while simultaneously 
supressing osteoblast activity in the osseous tissue), 
enhances calcification processes in vascular walls, and 
is associated with bone mass losses in postmenopausal 
women [2]. However, one article reports the opposite, 
with the suggestion that cholesterol levels in young and 
middle-aged patients do not appear to have long-term 
clinical implications for osteoporosis [22]. 
Statistical evaluation demonstrated higher fatal 
CVD risk in patients with osteoporosis vs. those with-
out osteoporosis, while there were an equal number 
of cardiological diseases. It may suggest that, besides 
cardiological conditions, there might have been another 
CVD mortality risk factor in the study group, such as 
osteoporosis. This situation may, as emphasised in many 
studies, be influenced by the correlation between low 
bone mineral density and the occurrence of calcifica-
tions in arteries, in the aorta and in cusps of the aortal 
valve, which is observed in postmenopausal women 
[1, 4, 7] (aortal calcification is an independent factor, 
predicting low BMD levels [7]). Another correlation 
has also been documented, namely that between de-
creased BMD and increased arterial stiffness, observed 
in hypertensive patients [3]. 
The higher cardiovascular death risk among the 
patients of the study group may suggest the presence 
of an additional risk factor, which is common for both 
osteoporosis and CVD. It is important here to consider 
osteoporosis and metabolic markers associated with this 
disease. It appears from the literature that the under-
taken studies rarely evaluate bone metabolism markers 
with reference to ischaemic heart disease. It is postu-
lated that multiple factors, e.g. osteoprotegerin, para-
thyroid hormone, phosphates, vitamins D and K, seem 
to be involved in both osteoporosis and CVD [23]. Only 
scarce reports indicate that osteoprotegerin most effec-
tively illustrates the bone-arterial relationships [5, 18] 
and, while controlling osteoclast activity and func-
tions, it also influences the process of calcification and 
atherosclerosis (90% of atherosclerotic plaques undergo 
calcification), being also associated with an increased 
risk of diabetes mellitus and death from cardiovascular 
disease [2]. It is also reported that BMPs (bone mor-
phogenetic proteins), ALP (alkaline phosphatase), and 
OPN (osteopontin) — factors involved in osteogenesis 
— are correlated with vascular calcification [19]. In the 
literature there is also suggestion that osteocalcin is 
important not only for bones but also for glucose and 
fat metabolism [24].
In the osteoporosis group there was a higher 
percentage of patients supplemented with calcium 
compounds and exercising with physical effort on 
a daily basis. It may have resulted from compliance 
with medical recommendations in that particular condi-
tion — it might be obvious that those patients strictly 
undergo secondary prevention (but it might be also 
a paradox that active patients who supplement calcium 
have higher risk of osteoporosis).
Conclusions
Summing up, in our study the high 10-year risk of 
death from cardiovascular diseases was more frequent 
in patients with osteoporosis, the mean 10-year risk 
of fatal CVD was higher in the group of patients with 
osteoporosis, and EHS negatively correlated with 
T-score of the Neck, Total Hip, and L2-L4 in the whole 
study population and with Neck T-score in the control 
group. The EuroHeart Score also correlated with the 
10-year risk of major and femoral neck fractures in the 
whole study population and in the group of patients 
with osteoporosis. Besides, regarding this group, there 
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was a higher fatal CVD risk in those with osteoporosis 
vs. those without osteoporosis, with the same number 
of cardiological diseases in both groups. Taking into 
account the demonstrated correlations, basic cardio-
logical diagnostic methods (ECG, lipids, arterial blood 
pressure) are suggested in patients with osteoporosis 
and, vice-versa, basic examinations towards bone me-
tabolism disorders (total calcium and vitamin D levels) 
are recommended in cardiological patients because 
simple screening may help prevent potentially more 
serious consequences. A more detailed analysis of 
this issue is highly justified (mostly for the rather low 
number of patients in the presented study), although 
the indicated statistical significance and conformity 
with literature reports improve the reliability of the 
attained results. We are aware of the limitations of our 
study, especially the small number of patients in the 
study groups. This was a pilot study — it is planned 
to conduct the study on a greater number of patients 
in the future.
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